ity-adjusted life-years (QALYs), was calculated for patients receiving ADAϩMTX, IFXϩMTX, and MTX alone. Outcomes were examined separately for MTX-naïve and disease-modifying antirheumatic drug (DMARD)-failure patients. Treatment benefits were measured by American College of Rheumatology 20, 50, and 70 responses and translated into improvements in Health Assessment Questionnaire Disability Index scores. Risks comprised loss of drug efficacy and adverse events; patients could withdraw from treatment due to either. Benefits and risks were associated with increments and decrements in QALYs, respectively. Data were derived from the published literature and drug prescribing information. RESULTS: MTX-naïve patients on ADAϩMTX, IFXϩMTX, and MTX alone withdrew after 3.31, 2.46, and 2.71 years and accrued NHBs of 1.40, 1.05, and 1.08 QALYs, respectively. Thus, MTX-naïve patients on ADAϩMTX accrued incremental NHBs of 0.35 (P Ͻ .05) versus IFXϩMTX and 0.32 (P Ͻ .05) versus MTX alone. DMARD-failure patients on ADAϩMTX, IFXϩMTX, and MTX alone withdrew after 3.33, 2.11, and 1.44 years and accrued NHBs of 1.38, 0.86, and 0.57 QALYs, respectively. Thus, DMARD-failure patients on ADAϩMTX incurred incremental NHBs of 0.51 (P Ͻ .05) versus IFXϩMTX and 0.81 (P Ͻ .05) versus MTX alone. CONCLUSIONS: Understanding the benefitrisk tradeoff is important for clinicians when prescribing anti-TNFs. Both MTXnaïve and DMARD-failure patients may experience greater NHB when treated with ADAϩMTX than when treated with IFXϩMTX or MTX alone. The GO-REVEAL clinical trial has shown golimumab to be effective in the treatment of active and progressive PsA. A recently published article by Yang et al. that covered the NICE technology appraisal process for psoriatic arthritis (TA220) presented an indirect comparison that suggested differences in treatment effects between different anti-Tumor Necrosis Factor-ainhibitors (TNFs). OBJECTIVES: To evaluate the comparative efficacy of anti-TNF drugs for the treatment of PsA in patients with an inadequate response to disease-modifying anti-rheumatic drugs (DMARDs) using a a critical appraisal of the Yang et al. manuscript and network meta-analysis.
OBJECTIVES:
Chronic inflammation in rheumatoid arthritis (RA) may interfere with bone remodelling. Small studies have suggested biologic DMARDs preserve bone mineral density at 6-12 months. Our objective was to determine the risk of non-vertebral osteoporotic fractures in RA subjects aged Ն50, comparing outcomes in patients who were exposed or unexposed to biologic DMARDs. METHODS: A nested case-control study from January 2002 to December 2008 was conducted using Quebec physician billing and hospital discharge data. RA subjects were identified from ICD-9/10 codes in billing and hospitalization data. Subjects were followed until the earliest of non-vertebral osteoporotic fracture (index date), death, or end of study period. A validated algorithm identified non-vertebral osteoporotic fractures from physician claims. Controls were matched to cases (4:1 ratio) on age, sex, and date of study entry. Biologic DMARD exposure was defined as being on treatment for Ն180 days pre-index. Conditional logistic regression was used, adjusting for indicators of RA severity, comorbidity, drugs influencing fracture risk, and measures of health care utilization. RESULTS: Over the study period, 1,803 cases were identified (7,175 controls). The most frequent fracture site was hip/ femur (43.7%). In total, 190 subjects (53 cases, 137 controls) were exposed to biologic DMARDs. We were unable to demonstrate an association between biologic DMARDs and fracture risk (Odds Ratio, OR [95% Confidence Interval, CI]: 1.16 [0.51-2.62]). RA duration had the strongest impact on fracture risk; for subjects of RA duration Ն10 years (vs. Ͻ5), the OR was 6.40 (95% CI 3.57-11.46), while those with RA duration 5-10 years (vs. Ͻ5) had an OR of 3.05 (95%CI 1.90-4.89). The inability to detect an effect remained in sensitivity analyses. CONCLUSIONS: Despite the positive impact of biologic DMARDs on bone remodelling observed in small studies, we were unable to demonstrate a reduction in the risk of non-vertebral osteoporotic fractures in older adults with RA. Heiman F, Katz P, Pegoraro V CSD Medical Research S.r.l., Milan, Italy OBJECTIVES: In Italy the epidemiological data and the Dupuytren disease care practice description are poor and come mainly from extrapolation of data obtained in other countries. The objective of this study was to assess the prevalence and the management of this disease in Italy and in the Italian regions. METHODS: Data have been obtained from CSD LPD General Practitioner's (GPs) longitudinal database. Patients with at least one diagnosis of Dupuytren disease between October 2008 and September 2010 were selected. Patients were followed-up for 12 months since the First Diagnosis date. Study results have been stratified by macro areas. RESULTS: 1.829 patients (62,55% men, 37,45% women) with at least one diagnosis of Dupuytren disease have been selected. Disease prevalence was estimated at 0,15% patients nationwide and at 0.178% , 0.229%, 0.123% ,0.082% patients in the NordWest, Nord-East, Center and South-Islands respectively. Prevalence increased with age: 35% of the patients were aged over 65 y. Only 32 % of the patients benefited from a specialist visit request for the Dupuytren disease during the follow-up period; 70,7% of those requests were for orthopedic visits, 13,5% for hand surgery and 7,5% for physiatry. Macro area analysis showed some differences in the specialists visits distribution. CONCLUSIONS: The prevalence analysis showed a slight difference among macro areas underlining a major prevalence of the disease in the Nord-East compared to the South-Islands area. The prevalence of the disease in the CSD LPD database in Italy was of 0.15% which is significantly lower than that reported in the literature. This is probably due to the fact that the majority of Dupuytren published studies were conducted in Nordic countries where the disease is mainly diffused. Also, the data collection methods and the age groups could be different, and, further, many researches were carried out in a specialist setting only. 
PMS8 DUPUYTREN DISEASE IN ITALY: A STUDY BASED ON A GPS LONGITUDINAL PATIENT DATABASE

MUSCULAR-SKELETAL DISORDERS -Cost Studies
PMS9 BUDGET IMPACT OF USING SUGAMMADEX FOR THE ROUTINE REVERSAL OF NEUROMUSCULAR BLOCKADE IN A GREEK HEALTH CARE SETTING
OBJECTIVES:
To model the annual impact on hospital costs following the introduction of sugammadex for routine reversal of neuromuscular blockade.
METHODS:
An economic model reflecting resource use and costs associated with neuromuscular block and its reversal, and residual blockade, was constructed for a typical Greek hospital. Clinical trial data were used to estimate time savings relating to shortened reversal in the operating room (OR) for sugammadex compared to neostigmine and no reversal. Costs of OR time were derived from labor costs for different types of OR staff. Resource use associated with residual blockade sequelae (aspiration, hypoxemia, muscle weakness, upper airway obstruction) was estimated from the literature. Annual procedures, utilization of neuromuscular blocking and reversal agents, and uptake of sugammadex within a typical Greek hospital were estimated. Unit costs were based on public data sources or published literature. RESULTS: If all OR staff modeled (with average staff attendance across all procedures of 2.4 anesthetists, 3.5 surgeons and 3.7 nurses) can realize time savings with shortened reversal, use of sugammadex is estimated to save a typical Greek hospital, using sugammadex in 7,130 procedures annually, 23,717 € per year. This corresponds to an increase in drug costs of 358,963 €, which is more than fully offset by a decrease in costs of OR staff and clinical sequelae of residual blockade (-382,680 €) . In a worst case scenario, if only one second degree anesthetist, one second degree surgeon and one nurse in attendance realize time savings, annual costs would be increased (198,404 €) . Results were sensitive to OR staff costs and time savings. CONCLUSIONS: Sugammadex for routine reversal of neuromuscular blockade can potentially lead to cost savings in the Greek health care setting. The degree to which costs may be saved depends upon which OR staff can realize time savings with shortened reversal. OBJECTIVES: To assess differences in treatment costs for patients with anti-TNFs for ankylosing spondylitis (AS) and rheumatoid arthritis (RA), according to their route of administration. METHODS: A budget impact analysis was designed to study the costs of each administration route, whether administered subcutaneously (SC) in the ambulatory setting or administered intravenously (IV) in an outpatient hospital setting, from the perspective of the French Statutory Health Insurance. Costs and tariffs are official statutory tariffs. The dosages of each treatment stem from the Summary of Product Characteristics. Costs were followed-up over 2 years (induction ϩ maintenance). For the weight, a gold standard of 70 kg was considered. Scenarios were modeled for cohorts of 100 patients. Costs for nurse have been systematically taken into account for each SC injection associated to a specialist consultation every 3 months. Initially for IV drugs no ambulatory additional costs and no transportation costs were considered. RESULTS: For AS, the average cost for SC drugs over 2 years was 23 471€ while it was 31 086€ for infusion A440 drugs. For RA, average cost for SC drugs was 24 448€ and it was 30 403€ for the infusion drugs. For 100 AS patients treated over 2 years, substituting 60% of IV by SC drugs would generate 353 013€ in savings for the French Statutory health insurance. For RA, such a substitution would yield a 487 977€ saving. Taking into account transportation costs of 50€ per visit increased respectively the costs associated with infusion therapies to 31 153€ for AS and 31 085€ for RA. CONCLUSIONS: In the context of ever-increasing scrutiny over public health care expenditure, differences in costs should drive the choice of treatment route of administration. Overall, replacing current IV Anti-TNF therapies by SC treatments would entail substantial benefits for the French Statutory Health Insurance. 
PMS10 COMPARING COSTS OF ANTI-TNF THERAPY BY ADMINSTRATION ROUTE FOR PATIENTS WITH ANKYLOSING SPONDYLITIS AND RHEUMATOID ARTHRITIS IN FRANCE IN 2012: A BUDGET IMPACT MODEL
PMS11 BUDGET IMPACT ANALYSIS IN SPANISH PATIENTS WITH DUPUYTREN'S CONTRACTURE: FASCIECTOMY VERSUS COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
OBJECTIVES:
To estimate the budget impact analysis of Collagenase Clostridium histolyticum (CCH) vs. fasciectomy (FSC) for the treatment of Dupuytren's Disease (DD) in Spain. METHODS: A cost minimization analysis was adopted (effectiveness was assumed to be equivalent for both techniques). DD related costs were considered: CCH costs (including drug, administration and visits) were obtained from clinical trials and a real-life study. FSC costs (including type of admission, visits, emergency room, re-admissions, tests, drugs and rehabilitation costs) were collected through a retrospective, observational, local study. Unit costs were obtained from local databases (e-SALUD and BOT). Results were presented from the NHS perspective for the next 3 years. We assumed 5100 fasciectomies/year (ϩ5% annually) and a 20, 30 and 40% of them will annually utilize CCH. In addition a 10, 15 and 20% of untreated diagnosed patients were expected to receive CCH. All the data were validated through an expert panel. A sensitivity analysis was performed with the main variables. RESULTS: The average FSC cost was € 2250 (72% inpatients), ranging from € 1703 to € 2467 for outpatients and inpatients respectively. The average CCH cost was € 1220 (1.5 vial/injection and 4 visits) and may drop to € 898 (1.1 vial/injections and 3 visits). The accumulated 3 years BIA was 45,971 € [M€ -2.993, 3.870]. CONCLUSIONS: According to this study, the inclusion of the CCH produced a 3 years cumulative budgetary impact of € 45,971 [M€ -2.993, 3.870] for the NHS.
PMS12 BUDGET IMPACT OF GOLIMUMAB IN THE ANTI-TNF TREATMENT OF RHEUMATOID ARTHRITIS, AKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM
Morais AD, Pereira ML Janssen Cilag Farmaceutica, São Paulo, Brazil OBJECTIVES: To estimate the budget impact of adopting golimumab for the treatment of rheumatoid arthritis (RA), akylkosing spondilitis (AS) and psoriatic arthristis (PsA) in the Brazilian public health care system (SUS). METHODS: In Brazil, four anti-TNF biologics are approved for treatmenting RA, AS and PsA: adalimumab, etanercept, infliximab, and golimumab. However, only the former three are reimbursed in the SUS. Using the public database, DATASUS, the number of patients receiving anti-TNF treatment for RA, AS and PsA (based on ICD9 codes) was gathered for the last 12 months, along with the associated drug costs. As golimumab is not yet reimbursed, treatment cost was defined according to law, based on the mandatory government discount of 21,87% . RESULTS: Around 38.687 patients received treatment with adalimumab (18.802), etanercept (14.614) and infliximab (6.840) between March 2011 and February 2012 in the SUS for RA, AS and PsA. In total, public health care spending with these treatments was about R$ 1.005.311.920,00 for the three indications in the same period (average treatment cost/patient R$ 25.985,78). Assuming the adoption of golimumab in 30% of patients receiving subcutaneous treatment (adalimumab and etanercept), the budget will be reduced by about R$ 101 million (11%) in the first year, excluding taxes. These savings represent over 6.238 new patients/year that can receive treatment with golimumab for RA, AS, and PsA. The savings can reach up to R$ 303 million /year, if golimumab is adopted as first choice among subcutaneous anti-TNF treatments. CONCLUSIONS: With the lowest treatment cost, golimumab has the potential to reduce public expenditure across all three indications in the SUS. These savings have important benefits for payers and patients, such as an increase in access to treatment or investment in other health priorities. Furthermore, with the least frequent dosing, golimumab presents important advantages in terms of patient commodity and logistics. 
PMS13 COMPARATIVE BUDGET IMPACT OF TERIPARATIDE VERSUS PARATHORMONE 1-84 USING INDIRECT COMPARISON EFFICACY DATA IN ITALY
OBJECTIVES:
To estimate the budget impact for the treatment of osteoporosis in Italy following a treatment pattern with TERIPARATIDE vs. PTH 1-84. METHODS: A budget impact model was constructed using a decision-tree analysis with a Monte Carlo technique where a sufficiently large number (currently 500) of individual patients are processed through the model, saving the result for each patient and calculating a mean group cost. The model incorporates the vertebral fracture and non-vertebral fractures odd ratios for TERIPARATIDE vs. PTH 1-84 from the MTC of Migliore (2012).The odd ratios are held constant for the 18 months of treatment. The analysis was carried out from the perspective of the Italian health care system and therefore only direct costs were considered (drug costs and fracture costs). Vertebral and non-vertebral fracture costs for Italy were taken from Borgstrom (2011) and inflated to year 2012 using a national inflation index. The average nonvertebral fracture cost was calculated by adjusting the non-vertebral fracture costs to the probability of their incidence. The model integrates a univariate sensitivity analysis and a probabilistic sensitivity analysis. RESULTS: Within 500 Monte Carlo patient simulations, mean costs per patient were significantly different between the two alternatives with €11,408 (SD €4,478) and €13,280 (SD €4,643) for the TERIPA-RATIDE and PTH 1-84 group, respectively (p Ͻ 0.0001). The robustness of the study was confirmed through the univariate sensitivity analysis that has shown TERIPA-RATIDE to remain the cheapest therapeutic option also by decreasing the vertebral fractures odd ratio of PTH 1-84 up to 50% and through the probabilistic sensitivity analysis where TERIPARATIDE has shown the highest probability to be the cheapest therapeutic option. CONCLUSIONS: Considering the treatment costs and the costs of the fractures not avoided, TERIPARATIDE is expected to be the cheapest therapeutic option compared to PTH 1-84. 
PMS14 IMPACT OF SEVERITY INDEX FOR RHEUMATOID ARTHRITIS ON HEALTH CARE COSTS AND UTILIZATIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS
OBJECTIVES:
Examine the impact of a claims-based severity index for rheumatoid arthritis (RA) on health care costs and utilizations of RA patients using large U.S. claims data. METHODS: Adult patients with at least two RA diagnoses and 12 months of continuous health plan enrollment before and after the index date (first RA diagnosis date) were identified from a large U.S. claims database (10/1/2008 -09/30/2009). A severity index for rheumatoid arthritis (SIFRA) was developed by calculating a weighted sum of 34 RA-related indicators including laboratory, clinical and functional status, extra-articular manifestations, surgical history, and medications as assessed by an expert Delphi panel of six rheumatologists. The relationship between SIFRA terciles and health care utilizations and costs was also examined using histograms. A regression model was used to examine the improvement of the model fitting by adding SIFRA. RESULTS: A total of 23,951 RA patients (mean SIFRA: 9.14) with laboratory information were identified. Descriptive analysis showed that patients in the upper tercile of SIFRA incurred $9,123 more allcause health care costs and $1,326 more RA-related health care costs than patients in the lower tercile of SIFRA. The most dramatic difference between highest and lowest SIFRA terciles occurred with pharmacy costs ($6,860 vs. $1,919, pϽ0.001). Health care visits followed a similar to health care costs for SIFRA terciles. Patients in the highest SIFRA tercile had higher total office visits (110.14 vs. 77.16, pϽ0.001) and higher RA-related visits (6.72 vs. 3.93, pϽ0.001) compared to patients in the lowest tercile. Regression results showed that the model was more than 6-times (611%) superior in explaining the variation in outcomes after adding SIFRA into the model. CONCLUSIONS: SIFRA demonstrated evidence of being a significant determinant of health care costs and utilizations for RA patients. This study suggests that SIFRA could be an important methodological tool to control for severity in RA-related outcomes research. 
PMS15 DETERMINANTS OF TOTAL HEALTH CARE COSTS ASSOCIATED WITH ANKYLOSING SPONDYLITIS PREVALENT CASES IN TURKEY
OBJECTIVES:
Estimate risk-adjusted health care costs and identify associated risk factors for ankylosing spondylitis (AS) expenditures in Turkey using real-world data. METHODS: Research-identified data from a system that processes claims for all Turkish health insurance funds was analyzed. Adult prevalent AS patients with two AS visits at least 60 days apart, identified between June 1, 2010 and December 31, 2010, were required to have an AS diagnosis before June 1, 2010, with at least 1 year of continuous enrollment for the baseline and follow-up years. Pharmacy, outpatient and inpatient claims were compiled over the study period for the selected patients. RESULTS: Among 2,383 patients (mean age: 40.52; female: 38%), 51% were age 18-39, 46% were 40-64 years and 3% were age 65 or older. AS diagnoses were most prevalent in the Marmara region (46%), followed by Aegean (17%), Central Anatolia (22%), and Mediterranean (8%). Nearly 40% of AS patients had at least one cardiovascular, diabetic, respiratory, allergy, Crohn's disease, uveit and rheumatoid arthritis comorbid condition prior to AS diagnosis. 7% of patients were hospitalized and 46% had at least one outpatient visit during the pre-index period. Most patients were prescribed non-COX inhibitors (71%) and 35% of patients were prescribed disease-modifying anti-rheumatic drugs (DMARDs). Few patients (1%) had surgery prior to diagnosis. The total annual cost ( a 4,233) was comprised of mainly pharmacy ( a 3,760), followed by outpatient ( a 297), and inpatient costs ( a 155), and an average copay of a 21. Prior comorbid conditions including diabetes, respiratory disease as well as hospitalization, glucocorticoid and DMARD use significantly contributed to annual health care costs, unlike gender and age. CONCLUSIONS: Annual costs of AS patients are significantly lower in Turkey relative to other European countries, yet, pharmaceutical expenditures cover a significant portion of the overall cost. Comparative effectiveness studies are needed to further decrease pharmaceutical expenditures for AS treatment.
